Autologous Anti-CD83 CAR T-cells therapy(Roswell Park Cancer Institute)

N/A

Report date: 2026/03/26 20:00:17

Base Information

Drug NameAutologous Anti-CD83 CAR T-cells therapy(Roswell Park Cancer Institute)

Drug Alias NameN/A

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy

Mechanisms of ActionT lymphocyte replacementsAnti-CD83 Molecule

TargetsCD83 Molecule

Therapy Area/IndicationsLeukemia, Myeloid, Acute

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPhase 1 Clinical

Highest Status in ChinaN/A

Originator CompaniesRoswell Park Cancer Institute

China Registration ClassN/A

Develop Information

Active CompaniesRoswell Park Cancer Institute

Inactive CompaniesN/A

Active IndicationsLeukemia, Myeloid, Acute

Inactive IndicationsN/A

Other Information

ATC CodeN/A